PDCD1 and neoplasm: LOX inhibitor-mediated reduction of matrix stiffness has been shown to significantly enhance T cell tumor infiltration and migratory capacity, while synergistically potentiating the anti-tumor efficacy of PD-1/PD-L1 blockade therapy.